City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics

Jun 8

Written by Guest User

https://investors.citytx.com/news-releases/news-release-details/city-therapeutics-announces-995-million-series-b-financing

Press Release

City Therapeutics Appoints Keith Regnante, MBA, as Chief Financial Officer and Mary Beth DeLena, J.D., as Chief Legal Officer

City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting